TW537893B - A pharmaceutical composition for the prevention of migraine recurrence - Google Patents
A pharmaceutical composition for the prevention of migraine recurrence Download PDFInfo
- Publication number
- TW537893B TW537893B TW088110233A TW88110233A TW537893B TW 537893 B TW537893 B TW 537893B TW 088110233 A TW088110233 A TW 088110233A TW 88110233 A TW88110233 A TW 88110233A TW 537893 B TW537893 B TW 537893B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- migraine
- scope
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Description
經濟部智慧財產局員工消費合作社印製 537893 A7 _____ B7 五、發明說明(Μ 本發明係有關使用艾勒崔普,以製造預 防偏頭痛復發之一種藥劑。 曾顯示5-HT1B/1D受體同效劑,諸如一般稱作“崔普坦 (triptan)”之化合物,在治療偏頭痛方面非常有效。該崔普 坦衍生物包括艾勒崔普坦、舒馬崔普坦(sumatdpta)、納 拉崔普坦(naratriptan)、利澤崔普坦(rizatriptan)、周馬崔 普坦(zolmtriptaii)、艾莫崔普坦(alm〇triptan)及夫洛弗崔 普坦(frovatriptan)。 艾勒崔普坦,即3-([1-甲基吡咯烷基]甲基分 苯基續醢乙基)-1Η-吲哚,被揭露於w〇-A-92/06973。艾 勒崔普坦較佳的氫溴化物鹽被揭露於W〇-A-96/06842。 WO-A-99/01135揭露包含艾勒崔普坦半硫酸鹽與咖啡因之 藥學配方物。 偏頭痛一般分為二種類型,“具有先兆之偏頭痛,,與“ 無先兆之偏頭痛”。先兆為起始或伴隨發病之病灶神經症 狀之複徵。 具有先兆之偏頭痛一般界定為一種自發、復發性病 徵,其發作之神經症狀明確地可侷限於大腦皮層與腦幹 ,通常於5-20分鐘的期間逐漸地產生,及持續60分鐘以下 。通常在緊接著神經先兆病徵後,或在少於丨小時之無病 徵之時間間隔之後,產生頭痛、。惡心及/或畏光。偏頭痛 通常持續4至72小時,但可能完全消失。 無先兆之偏頭痛一般界定為一種自發、復發性病徵 ,其發作持續4至72小時。該偏頭痛之典型特徵為單向仇 (請先閱讀背面之注意事項再填寫本頁) 訂---------線*
537893 經十部智慧財產局員工消費合作社印製 A7 ----—-—---_____ 五、發明說明(2) 址、脈衝式品質、中等至嚴重之強度、因例行性身體活 動而加劇、及產生噁心、畏光或畏聲。 大部份的病人僅具有無先兆之偏頭痛。經常具有發 病先兆的病人,似乎亦以無先兆方式發病。“先兆病徵,,可 在偏頭痛發病(有或無先兆)前之數小時或一或二天前發生 。該等病徵一般包括機能亢進、活動減退、沮喪、對特 定食物之嗜慾、不斷打呵欠等一般特性與類似的非典型 病徵。 ^ 偏頭痛之復發係歸類為與偏頭痛本身不同的病況, 及界定為自第一次投予藥劑之2小時内無或僅輕微偏頭痛 的狀況下,在第一次投予藥劑之24小時内復發中度或嚴 重的偏頭痛。 證據顯示崔普坦衍生物可有效地抒解偏頭痛,該種 衍生物之使用,實際上使偏頭痛之復發依所用特定崔普 坦衍生物之特徵性速率產生。事實上,當使用崔普坦衍 生物時,每次偏頭痛後,偏頭痛復發的典型發病率約為3〇% 〇 需清楚地分辨該項治療究竟是治療已確立的偏頭痛 之偏頭痛的治療,抑或治療已確立的偏頭痛復發之偏頭 痛復發的治療,或者是治療預期偏頭痛復發之病人以避 免復發之偏頭痛復發的預防。應注意到並非所有病人皆 經驗到如上所界定之偏頭痛的復發。 迄今’尚未顯示曾有5-11丁18/10受體同效劑預防偏頭痛 之復發’對任一特定化合物而言此並非可預測者,即使 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱) Μ--------訂---------^ (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製
537893 A7 --~~--- 五、發明說明(3) 其之前曾用於治療偏頭痛。誠然,目前並未指出“崔普坦” 可預防偏頭痛之復發。偏頭痛復發之預防之所以無法預 測之原因,在於尚未瞭解偏頭痛復發之病原學。更進一 步,有關具有復發偏頭痛傾向之病人的特徵或,另類地 ,有關可能復發之偏頭痛的特徵之瞭解相當地少。
Cephalagis 第 14期第 330-338 頁(1994年)揭露 100 亳克 之舒馬崔普坦口服劑量,可在2小時内消弭約6〇%之偏頭 痛,但頭痛可能在24小時内復發。若在2小時後投予第二 片劑,並無法增加起始效用,亦無法預防或延緩偏頭痛 之復發。然而,在治療確立的偏頭痛之復發方面,進一 步投予舒馬崔普坦·片劑則非常有效。更進一步,Neur〇1〇gy 第45期第1505-1509頁(1995年)揭露,以6毫克之舒馬崔普 坦皮下劑量治療成功的偏頭痛中,約4〇%在24小時内可能 發生偏頭痛之復發。然而,在投予起始的6亳克舒馬崔普 坦皮下劑量4小時後,服用1〇〇毫克舒馬崔普坦口服劑量 ,並未預防偏頭痛之復發,但顯著地延緩偏頭痛復發之 時間。 目前意外地發現艾勒崔普坦可用以預防偏頭痛之復 發。 因此,本發明係有關艾勒崔普坦或其藥學上可接受 之鹽類或組成物用於製造一用以預防偏頭痛復發之藥劑 的用途。 更進一步,本發明係有關一種用於預防偏頭痛復發 之方法’其包括對病人投予一有效量之艾勒崔普坦或其
本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐)
(請先閱讀背面之注意事項再填寫本頁) --------訂---------線- 537893 經 濟, 部 智 慧· 財 產 局 員 工 消 費 合 作 社 印 製 A7 五、發明說明(4 ) 藥學上可接受之鹽類或組成物。 又勒崔普坦樂學上可接受之鹽類包括其酸性加成戋 驗性鹽類。 適宜的酸性加成鹽類係自酸形成無毒的鹽類,其實 例為氫氣化物、氫溴化物、氫碘化物、硫酸鹽、硫酸氫 鹽、硝酸鹽、磷酸鹽、氫磷酸鹽、乙酸鹽、順式丁烯二 酉欠鹽、反式丁烯二酸鹽、乳酸鹽、酒石酸鹽、檸檬酸鹽 、葡萄糖酸鹽、琥珀酸鹽、糖質酸鹽、苯甲酸鹽、甲磺 酸鹽、乙磺酸鹽、苯磺酸鹽、對_曱苯磺酸鹽及雙羥萘酸 鹽。 適且的驗性加成鹽類係自驗形成無毒的鹽類,其實 例為鈉、鉀、鈣、鎂與鋅鹽。 有關適宜鹽類的回顧評論詳見Berge等人於j. pharm. Sci· ’ 1977年第66期第1-19頁乙文。 用於本發明之艾勒崔普坦較佳鹽類為氫溴化物與硫 酸鹽類,包括半硫酸鹽類。 本發明之範疇亦包括艾勒崔普坦之多晶形物、溶化 物及放射性標示之衍生物,及其藥學上可接受之鹽類。 艾勒崔普坦之藥學上可接受的溶化物與其藥學上可 接受之鹽類包括其水合物。 艾勒崔普坦藥學上可接受之鹽類,可藉由適宜地混 合艾勒崔普坦溶液與所需的酸或鹼而製備。該鹽類可自 /谷液沈澱及以過濾方法收集,或藉由蒸發溶劑而加以回 收0 本紙張尺ϋ中闕家標準(CNS)A4規格(21。x 297公爱) -------------裝--------訂---------線 (請先閱讀背面之注音?事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製
537893 艾勒崔普坦或其鹽類可單 摒金夕批—A J早獨施用,但一般摻合依所 旦又樂途徑與標準藥學慣例而
劑、稀釋劑或載體而施用β I且樂予賦I “如x勒崔普坦或其鹽類能以含有增香劑或著色 ㈣,用於立即釋出或控制釋出應用之片劑、膠囊、印狀 小體、_、溶液«浮液之形式而σ服或舌下投藥。 I片可含有諸如微結晶纖維素、乳糖、檸檬酸納 、碳酸鈣、磷酸二鈣及甘胺酸之賦形劑,可含有崩解劑 諸如搬粉、可洛斯梅羅(croscarmeI1〇se)鋼及一些複合石夕酸 鹽’可含有成粒作⑽合劑諸如聚乙稀基料院嗣、薦 糖、明膠及金合歡。此外亦可包括諸如硬脂酸鎂、丙三 基本合耐特(benhenate)及滑石之潤滑劑。 、在明,膠膠囊中,亦可使用類似種類的固態組成物作 ^填料。就該方面而言,較佳之賦形劑包括乳糖以及高 刀子至:1乙一醇。就含水懸浮液及/或醜劑而言,艾勒崔 、曰i一或其鹽類此與各種甜味劑或增香劑、著色物質或染 料,或與乳化及/或懸浮劑,及與諸如水、乙醇、丙二醇 及丙三醇之稀釋劑,及其組合物併用。 艾勒崔普坦或其鹽類亦能非經腸地以注射方式施用 ,諸如以靜脈、腹膜内、椎管内、心室内、胸骨内、顱 内、肌内或皮下注射,或藉由注射技術而投予。最佳係 以無菌水溶液之形式使用,其可含有其他物質,諸如足 量的鹽與葡萄糖以使得溶液與血液等張。若需要,應適 宜地緩衝水溶液(較佳pH值自3至9)。以習知技藝者所熟知 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
δ 發明說明(6) 之“準藥予技術’即可在無菌條件下s a適宜的非經腸 配方物之製備。 、就對病人之口服與非經腸的投藥而言,艾勒崔普坦 或其鹽類之每曰劑量一般自01至4毫克/公斤(以單一或分 開的劑量)。 艾勒崔普坦或其鹽類之片劑或膠囊,可含有5至240 毫克,較佳5至1〇〇毫之活性化合物,視需要以單個或一 人一或夕個之方式投藥。在各情況下醫師將決定最適合 個別病人之實際劑量,其依該特定病人之年齡、體量及 反應而異。上述劑量係一般病例之示範劑量。當然,在 個別情況下可使用較高或較低之劑量範圍,其亦涵蓋於 本發明之範鳴内。 艾勒崔普坦或其鹽類亦能以鼻内或吸入方式投予, 八:乂乾燥粕末吸入器之形式或以使用適宜的推進劑之 加壓容器或噴霧器之氣膠喷霧呈現方式而方便地達成, 推進劑如二氯二氟甲烷、三氣氟甲烷、二氣四氟乙烷、 諸如u,i,2-四氟乙烧([商標]HFA 134A)或 氟丙烷([商標]HFA 227EA)之氫氟烷、二氧化碳或其他適 宜的氣體。在加壓氣膠之情況下,劑量單位可藉由提供 一個傳送經儀表計數之量的闊而測定。加壓容器或噴霧 器可含有活性化合物之溶液或懸浮液,如使用乙醇與推 進劑作為溶劑之混合物,其另外可含有潤滑劑如三油酸 =梨聚糖酯。用於吸入器或吹藥器中之膠囊與藥筒(例如 製備自明膠),可配方含有艾勒崔普坦或其鹽類之粉末混 537893 A7 經濟部智慧財產局員工消費合作社印製
(請先閱讀背面之注意事項再填寫本頁} 五、發明說明(8) 型包括; ⑷其中:勒崔普坦或其藥學上可接受之鹽類包埋於 土之中,藉由擴散作用或侵蝕作用而釋出, 、、⑻其中艾勒崔普坦或其藥學上可接受之鹽類存在於 塗覆有速率控制膜之多微粒核心之中或之上, ⑷其中艾勒崔普坦或其藥學上可接受之鹽類所存在 齊j 3L s有藥物無法滲透之外膠,而藥物係經由鑽孔 釋出, ⑷其中艾勒崔普坦或其藥學上可接受之鹽類經由半 渗透膜而釋出,容許藥物擴散通過該膜或經過膜内充滿 液體之孔,及 (e)其中艾勒崔普垣以離子交換錯合物存在,其能有 效地作用為活性化合物之控制釋出型的“鹽類,,形式(如藉 由使用-種適宜的陰離子交換樹脂諸如確酸聚苯乙婦納) 白知技藝者將明瞭部份上述達成持續釋出之方法, 旎與含有活性化合物之基質併用,該活性化合物可製成 夕Μ粒及/或以具有一個小孔之不滲透外膠塗覆。 脈波釋出型配方物之設計,係在對病人投予該劑型 後之持續期間,以脈波型式釋出活性化合物。屆時能以 立即或持續之形式釋出。釋出作用之延緩,可藉由在胃 腸道之特定點釋出藥物或在預定時間之後釋出藥物而達 成。脈波釋出型配方物,可為片劑或多微粒之形式,或 為一者之組合。適宜的劑型包括·· 本紙張尺度適用中國國家標準(CNS)A4規格(2】0 X 297公爱1 :~Π~- 537893 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(9) Ο)滲透勢引發之釋出形式(如見美國專利第3,952,741 號), (b) 壓縮具有外膠之二個片劑(如見美國專利第 5,464,633號), (c) 含有一個可侵蝕性栓之膠囊(如見美國專利第 5,474,784號), (d) S型釋出丸劑(如美國專利第5,112,621號所指出), (e) 塗覆或包含PH相依性聚合物之配方物,該等聚合 物包括蟲膠、酞酸鹽衍生物、聚丙烯酸衍生物及丁烯酸 共聚物。 雙重釋出型配方物可結合立即釋出形式之活性化合 物與持續釋出形式之額外的活性化合物。例如,雙層片 劑能以含有立即釋出形式之艾勒崔普坦之一層,與含有 包埋於基質中之艾勒崔普坦及藉由擴散或侵蝕作用而釋 出之另一層而形成。雙重釋出型配方物亦可結合立即釋 出形式之活性化合物與脈波釋出形式之額外的活性化合 物。例如含有一個可侵蝕性栓之膠囊,可在最初之際釋 出活性化合物,及在一段預定之時間之後進一步以立即 或持續方式釋出活性化合物。 較佳之藥物雙重釋出分佈包括: (a) 立即型釋出後,接著為控制型釋出; (b) 立即型釋出後,接著為零級釋出; (C)立即型釋出後,接著為S型釋出;及 (d)雙脈波型釋出。 (請先閱讀背面之注意事項再填寫本頁) --------訂---------線赢 本紙張尺—規格⑵〇 X 297公釐) 12 537893 經免部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(10) 延緩釋出型配方物之設計,係在投藥一段預定時間 之後釋出活性化合物。延緩釋出型配方物之釋出,可為 立即型或持續型之方式。 控制釋出型配方物,使得以控制活性化合物之釋出 速率或釋出時間,或二者,及包括持續型、脈波型及延 緩型配方物。 思外地發現,5-HT1B/1D^體同效劑或其藥學上可接受 之鹽類以雙重-、持續…延緩-、控制-或脈波-釋出型配方 物投予’可避免偏頭痛之復發。 其他適用之5-HT1B/1D^體同效劑實例包括舒馬崔普坦 ,納拉崔普坦,利澤崔普坦,周馬崔普坦,艾莫崔普坦 及夫洛弗崔普坦。 適用之雙重-、持續-、延緩-、控制_或脈波_釋出型配 方物,如上就艾勒崔普坦所述者。 因此,本發明進一步提供: a) 用以預防偏頭痛復發之雙重·、持續·、延緩_、控制 -或脈波-釋出型藥學組成物,其包括一種5_ΗΤι叫D受^同 效劑或其藥學上可接受之鹽類,及一種藥學上可接受之 賦形劑、稀释劑或載體; b) 使用5-HTib/id受體同效劑或其藥學上可接受之鹽類 或其組成物,以製造預防偏頭痛復發之雙重_、持續_、延 緩-、控制-或脈波·釋出型藥學組成物;及 C)一種預防偏頭痛復發之方法,其包括對病人投予有 效量之雙重·'持續·、延緩_、控制·或脈波_釋出型藥學 本紙張尺度適时關家標準(CNS)A4規格(210 X 297公爱 ^1 ϋ n 1 ϋ >ϋ I 1 n ϋ I I · i ϋ ϋ ·ϋ n ϋ ϋ· I n n I ϋ n _ϋ I (請先閱讀背面之注音?事項再填寫本頁) 537893 A7 B7 五、發明說明(n) 成物’其包含一種5-HT1B/1D^體同效劑或其藥學上可接受 之鹽類。 藥學數據 對感受到急性偏頭痛發病之病人,以片劑配方物方 式投予40或80毫克艾勒崔普坦(氫溴化物鹽類之形式)之口 服劑量。在最初劑量後之2小時内感受到偏頭痛抒解之所 有病人’若在投予最初劑量後之8小時内復發偏頭痛或未 復發偏頭痛,皆儘可能在投予最初劑量之8小時後,投予 艾勒崔普坦(氫溴化物鹽類之形式)之第二劑量(與最初投 予之強度相同),或投予安慰劑。 若病人在第一次發病之至少48小時後感受到第二次 急性偏頭痛發病,則童複上述程序。 所得第一與第二次偏頭痛發病後之偏頭痛復發率的 結果,表列於下。 (請先閱讀背面之注意事項再填寫本頁) --------訂— 經濟部智慧財產局員工消費合作社印製 劑量投予 順序 40毫克-安慰劑 40毫克-40毫克 80毫克- 安慰劑 80毫克-80毫克 第一次發病 RR% 16.6 7.0 12.5 6.2 第二次發病 RR% 10.2 3.3 11.2 6.1 該表列之數據顯示艾勒崔普坦可預防偏頭痛之復發 ,因當於成功地治療首次偏頭痛之後投予艾勒崔普坦第 二劑量時’感受到偏頭痛復發之病人人數較安慰劑組減 半0 本紙張尺度適用中國國家標準(CNS)A4規格(2〗〇x 297公釐) -14 - 爭
Claims (1)
- 537893六、申請專利範圍 第881 10233號專利再審查案申請專利範圍修正本 修正日期:92年2月 1 · 一種用以預防偏頭痛復發之藥學組成物,其包含艾勒 崔普坦(eletriptan)或其藥學上可接受之鹽類或組成物。 2·如申請專利範圍第丨項之藥學組成物,其中該鹽類為氫 溴化物鹽類。 3·如申請專利範圍第丨項之藥學組成物,其中該鹽類為半 硫酸鹽類。 4·如申明專利範圍第1項之藥學組成物,其中該藥學組成 物包括艾勒崔普坦半硫酸鹽與咖啡因。 5·如申請專利範圍第1項之藥學組成物,其中該藥學組成 物包括艾勒崔普坦或其藥學上可接受之鹽類,及一種 環糊精。 6·如申請專利範圍第丨項之藥學組成物,其中該藥學組成 物為艾勒崔普坦或其藥學上可接受之鹽類的雙重_、持 續-、控制-、延緩-或脈波_釋出型配方物。 申明專利範圍苐6項之藥學組成物,其中該藥學組成 物為乂勒崔普坦或其藥學上可接受之鹽類的雙重釋出 型配方物。 8·如申請專利範圍第丨項之藥學組成物,其包括艾勒崔普 坦或其藥學上可接受之鹽類,及一種藥學上可接受之 賦形劑、稀釋劑或載體。 9·如申請專利範圍第旧之藥學組成物,其係為_種用於 預防偏頭痛復發之雙重_、持續一控制一延緩_或脈波_ 537893 A B c D 申請專利範圍 ^^^ --- 釋出型藥學組成物,其包括艾勒崔普括、 接受之鹽類,及-種藥學上可接受或其藥學上可 或載體。 Μ形劑、稀釋劑 爪如申請專利範圍第9項之藥學組成物,其為雙重釋出型 組成物。 11.如申請專利範圍第8、9或10項之藥學組成物,其進一 步包括咖啡因或一種環糊精。 本紙張尺度適用中國國家標準(CNS) A4規格(2〗〇Χ297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9816556.6A GB9816556D0 (en) | 1998-07-30 | 1998-07-30 | Therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
TW537893B true TW537893B (en) | 2003-06-21 |
Family
ID=10836395
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088110233A TW537893B (en) | 1998-07-30 | 1999-06-17 | A pharmaceutical composition for the prevention of migraine recurrence |
TW092102563A TWI248362B (en) | 1998-07-30 | 1999-06-17 | A pharmaceutical composition for the prevention of migraine recurrence |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092102563A TWI248362B (en) | 1998-07-30 | 1999-06-17 | A pharmaceutical composition for the prevention of migraine recurrence |
Country Status (36)
Country | Link |
---|---|
EP (3) | EP1466601A3 (zh) |
JP (1) | JP3824863B2 (zh) |
KR (2) | KR20030078876A (zh) |
CN (2) | CN1155379C (zh) |
AP (1) | AP1402A (zh) |
AT (1) | ATE261304T1 (zh) |
AU (1) | AU3952199A (zh) |
BG (1) | BG65309B1 (zh) |
BR (1) | BR9912588A (zh) |
CA (1) | CA2338901C (zh) |
CZ (1) | CZ2001357A3 (zh) |
DE (1) | DE69915486T2 (zh) |
DK (1) | DK1100499T3 (zh) |
EA (2) | EA004036B1 (zh) |
EE (1) | EE04703B1 (zh) |
ES (1) | ES2214027T3 (zh) |
GB (1) | GB9816556D0 (zh) |
GE (2) | GEP20063719B (zh) |
HK (1) | HK1038198A1 (zh) |
HR (1) | HRP20010079A2 (zh) |
HU (1) | HUP0103424A3 (zh) |
ID (1) | ID26996A (zh) |
IL (1) | IL140169A0 (zh) |
IS (1) | IS2253B (zh) |
NO (1) | NO20010489L (zh) |
NZ (2) | NZ508736A (zh) |
OA (1) | OA11576A (zh) |
PL (1) | PL194611B1 (zh) |
PT (1) | PT1100499E (zh) |
SG (1) | SG125910A1 (zh) |
SK (1) | SK1182001A3 (zh) |
TR (1) | TR200100314T2 (zh) |
TW (2) | TW537893B (zh) |
UA (1) | UA76399C2 (zh) |
WO (1) | WO2000006161A1 (zh) |
YU (2) | YU20303A (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
CN1176649C (zh) * | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
CA2509023C (en) * | 2002-12-26 | 2011-05-24 | Pozen Inc. | Multilayer dosage forms containing nsaids and triptans |
BRPI0409127A (pt) | 2003-04-11 | 2006-03-28 | Pfizer | combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
FR2926721B1 (fr) * | 2008-01-30 | 2011-07-22 | Philippe Perovitch | Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans |
US8618157B2 (en) | 2008-06-20 | 2013-12-31 | Alphapharm Pty. Ltd. | Pharmaceutical formulation |
CA2815437A1 (en) | 2009-10-23 | 2011-04-28 | Fortuderm, Ltd. | Triptans for the treatment of psoriasis |
EP2838517B1 (en) * | 2012-04-18 | 2017-10-18 | Contera Pharma APS | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
CN103385876B (zh) * | 2012-05-08 | 2016-01-13 | 四川滇虹医药开发有限公司 | 一种夫罗曲坦的药物组合物及其制备方法 |
CN104523709A (zh) * | 2014-12-22 | 2015-04-22 | 青岛正大海尔制药有限公司 | 一种含有琥珀酸夫罗曲坦的复方缓释制剂 |
JP7227896B2 (ja) | 2016-07-11 | 2023-02-22 | コンテラ ファーマ エー/エス | 朝の無動状態を治療するための拍動性薬物送達系 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006973A1 (en) * | 1990-10-15 | 1992-04-30 | Pfizer Inc. | Indole derivatives |
ES2106818T3 (es) * | 1991-10-30 | 1997-11-16 | Glaxo Group Ltd | Composicion multicapa que contiene antagonistas de histamina o secotina. |
US5464633A (en) * | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
US5744482A (en) * | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
KR20000022239A (ko) * | 1996-07-11 | 2000-04-25 | 토마스 헤인 | 인돌 선택성 세로토닌 작용약을 함유한 내포 복합체 |
ID24528A (id) * | 1997-07-03 | 2000-07-20 | Pfizer | Komposisi-komposisi obat farmasi yang mengandung eletriptan hemisulfat dan kafein |
US6514530B2 (en) * | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
-
1998
- 1998-07-30 GB GBGB9816556.6A patent/GB9816556D0/en not_active Ceased
-
1999
- 1999-06-14 GE GEAP19996881A patent/GEP20063719B/en unknown
- 1999-06-14 CN CNB998087378A patent/CN1155379C/zh not_active Expired - Fee Related
- 1999-06-14 AP APAP/P/2001/002056A patent/AP1402A/en active
- 1999-06-14 JP JP2000562016A patent/JP3824863B2/ja not_active Expired - Fee Related
- 1999-06-14 OA OA1200000354A patent/OA11576A/en unknown
- 1999-06-14 EP EP04004643A patent/EP1466601A3/en not_active Withdrawn
- 1999-06-14 DE DE69915486T patent/DE69915486T2/de not_active Expired - Fee Related
- 1999-06-14 EE EEP200100061A patent/EE04703B1/xx not_active IP Right Cessation
- 1999-06-14 ES ES99922459T patent/ES2214027T3/es not_active Expired - Lifetime
- 1999-06-14 AU AU39521/99A patent/AU3952199A/en not_active Abandoned
- 1999-06-14 EP EP04004644A patent/EP1435237A1/en not_active Withdrawn
- 1999-06-14 CN CNA2003101025101A patent/CN1522697A/zh active Pending
- 1999-06-14 SK SK118-2001A patent/SK1182001A3/sk unknown
- 1999-06-14 CZ CZ2001357A patent/CZ2001357A3/cs unknown
- 1999-06-14 GE GEAP19995732A patent/GEP20043157B/en unknown
- 1999-06-14 BR BR9912588-9A patent/BR9912588A/pt not_active Application Discontinuation
- 1999-06-14 NZ NZ508736A patent/NZ508736A/en unknown
- 1999-06-14 IL IL14016999A patent/IL140169A0/xx unknown
- 1999-06-14 TR TR2001/00314T patent/TR200100314T2/xx unknown
- 1999-06-14 EA EA200100089A patent/EA004036B1/ru not_active IP Right Cessation
- 1999-06-14 KR KR10-2003-7008744A patent/KR20030078876A/ko not_active Application Discontinuation
- 1999-06-14 YU YU20303A patent/YU20303A/sh unknown
- 1999-06-14 UA UA2001010653A patent/UA76399C2/uk unknown
- 1999-06-14 ID IDW20010229A patent/ID26996A/id unknown
- 1999-06-14 DK DK99922459T patent/DK1100499T3/da active
- 1999-06-14 PL PL99345803A patent/PL194611B1/pl not_active IP Right Cessation
- 1999-06-14 WO PCT/IB1999/001105 patent/WO2000006161A1/en active IP Right Grant
- 1999-06-14 EP EP99922459A patent/EP1100499B1/en not_active Expired - Lifetime
- 1999-06-14 HU HU0103424A patent/HUP0103424A3/hu unknown
- 1999-06-14 PT PT99922459T patent/PT1100499E/pt unknown
- 1999-06-14 YU YU6401A patent/YU6401A/sh unknown
- 1999-06-14 AT AT99922459T patent/ATE261304T1/de not_active IP Right Cessation
- 1999-06-14 KR KR10-2001-7001231A patent/KR100441732B1/ko not_active IP Right Cessation
- 1999-06-14 CA CA002338901A patent/CA2338901C/en not_active Expired - Fee Related
- 1999-06-14 SG SG200300769A patent/SG125910A1/en unknown
- 1999-06-14 EA EA200201149A patent/EA200201149A1/ru unknown
- 1999-06-17 TW TW088110233A patent/TW537893B/zh not_active IP Right Cessation
- 1999-06-17 TW TW092102563A patent/TWI248362B/zh not_active IP Right Cessation
-
2000
- 2000-12-15 IS IS5771A patent/IS2253B/is unknown
-
2001
- 2001-01-29 NO NO20010489A patent/NO20010489L/no not_active Application Discontinuation
- 2001-01-30 HR HR20010079A patent/HRP20010079A2/hr not_active Application Discontinuation
- 2001-02-20 BG BG105277A patent/BG65309B1/bg unknown
- 2001-12-27 HK HK01109100A patent/HK1038198A1/xx not_active IP Right Cessation
-
2003
- 2003-08-15 NZ NZ527625A patent/NZ527625A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW580398B (en) | Effervescent formulations | |
TW537893B (en) | A pharmaceutical composition for the prevention of migraine recurrence | |
AU2006256518B2 (en) | Method and composition for treating inflammatory disorders | |
RU2221563C2 (ru) | Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона | |
US20050272717A1 (en) | Treatment of aromatase inhibitor therapy-related osteoporosis | |
JP2006528237A (ja) | バレニクリンの医薬組成物 | |
AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
CN101193622A (zh) | 治疗炎性疾病的方法和组合物 | |
PL194702B1 (pl) | Powlekana kompozycja farmaceutyczna w stałej postaci dawkowania i lek zawierający tę kompozycję | |
KR100708560B1 (ko) | 미르타자핀을 포함한 경구 붕해성 조성물 | |
AU2004287257B2 (en) | Oral formulations for 5-HT-receptor agonists, uses and methods of treatment employing the same | |
WO1998024411A2 (en) | Method for oral administration of buspirone | |
CA2538523A1 (en) | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin | |
US5216019A (en) | Pain killer | |
TW201202232A (en) | Treatment of GIST with masitinib | |
TW200425914A (en) | Pharmaceutical tablet composition comprising n-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide (sb 207266) or a salt thereof | |
JPH01207235A (ja) | 癌細胞転移抑制剤 | |
Wechter et al. | Pillsbury Winthrop LLP | |
MXPA01001097A (en) | Prevention of migraine recurrence | |
WO1999022730A1 (en) | Use of (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole for treating hyperalgesia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |